ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Browsing by Subject "Depressive Disorder, Major"
Now showing items 1-20 of 28
-
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
(The Journal of clinical psychiatry, 2013-07)<h4>Background</h4>Multiple treatments for patients with major depressive disorder (MDD) have demonstrated efficacy, but up to one-third of individuals with MDD do not achieve symptomatic remission despite various interventions. ... -
A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project.
(Annals of family medicine, 2019-07)<h4>Purpose</h4>This report describes outcomes of an ongoing quality-improvement project (VitalSign6) in a large US metropolitan area to improve recognition, treatment, and outcomes of depressed patients in 16 primary care ... -
Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness.
(Pharmacopsychiatry, 2019-03)In spite of multiple new treatment options, chronic and treatment refractory courses still are a major challenge in the treatment of depression. Providing algorithm-guided antidepressant treatments is considered an important ... -
Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.
(Translational psychiatry, 2021-03-02)Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major depressive disorder (MDD), yet their mechanisms of action are not fully understood and their therapeutic benefit varies among individuals. ... -
Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report.
(Translational psychiatry, 2021-08-04)Side effects to antidepressant medications are common and can impact the prognosis of successful treatment outcome in people with major depressive disorder (MDD). However, few studies have investigated the severity of side ... -
Can psychological features predict antidepressant response to rTMS? A Discovery-Replication approach.
(Psychological medicine, 2020-01)<h4>Background</h4>Few studies focused on the relationship between psychological measures, major depressive disorder (MDD) and repetitive transcranial magnetic stimulation (rTMS) response. This study investigated several ... -
Childhood maltreatment and impact on clinical features of major depression in adults.
(Psychiatry research, 2020-11)<h4>Objectives</h4>This study examined: 1) the prevalence of childhood maltreatment (CMT) in individuals with chronic and/or recurrent depression, 2) the association between CMT and depressive symptoms, 3) the link between ... -
Clinical research challenges posed by difficult-to-treat depression.
(Psychological medicine, 2022-02)Approximately one-third of individuals in a major depressive episode will not achieve sustained remission despite multiple, well-delivered treatments. These patients experience prolonged suffering and disproportionately ... -
Detection of depression in low resource settings: validation of the Patient Health Questionnaire (PHQ-9) and cultural concepts of distress in Nepal.
(BMC Psychiatry, 2016-03-08)BACKGROUND: Despite recognition of the burden of disease due to mood disorders in low- and middle-income countries, there is a lack of consensus on best practices for detecting depression. Self-report screening tools, such ... -
Differences in behavioral health disorders and unmet treatment needs between medical marijuana users and recreational marijuana users: Results from a national adult sample.
(Drug and alcohol dependence, 2017-11)BACKGROUND:Available data suggest that medical marijuana users may have more mental health problems than recreational marijuana users. There is limited information about differences in behavioral health disorders and unmet ... -
EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial.
(European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2021-03)Using pre-treatment biomarkers to guide patients to the preferred antidepressant medication treatment could be a promising approach to enhance its current modest response and remission rates. This open-label prospective ... -
ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries.
(Translational psychiatry, 2020-03)This review summarizes the last decade of work by the ENIGMA (Enhancing NeuroImaging Genetics through Meta Analysis) Consortium, a global alliance of over 1400 scientists across 43 countries, studying the human brain in ... -
Examining the factor structure of the Connor-Davidson Resilience Scale (CD-RISC) in a post-9/11 U.S. military veteran sample.
(Assessment, 2014-08)The present study examined the structural validity of the 25-item Connor-Davidson Resilience Scale (CD-RISC) in a large sample of U.S. veterans with military service since September 11, 2001. Participants (N = 1,981) completed ... -
Gender-specific structural abnormalities in major depressive disorder revealed by fixel-based analysis.
(NeuroImage. Clinical, 2019-01-08)<h4>Background</h4>Major depressive disorder (MDD) is a chronic disease with a large global impact. There are currently no clinically useful predictors of treatment outcome, and the development of biomarkers to inform clinical ... -
Gender-specificity of resilience in major depressive disorder.
(Depression and anxiety, 2021-10)<h4>Introduction</h4>The major stressors associated with the COVID-19 pandemic provide an opportunity to understand the extent to which protective factors against depression may exhibit gender-specificity.<h4>Method</h4>This ... -
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
(Translational psychiatry, 2019-07-04)Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain ... -
Modeling the onset of a depressive episode: A self-regulation perspective.
(Current opinion in psychology, 2021-04-21)Major depression is an episodic disorder which, for many individuals, has its onset in a distinct change of emotional state which then persists over time. The present article explores the utility of combining a dynamical ... -
Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
(Clinical pharmacology and therapeutics, 2019-10)We set out to determine whether machine learning-based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) ... -
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway.
(PloS one, 2013-01)Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to ... -
Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.
(The international journal of neuropsychopharmacology, 2019-05)<h4>Background</h4>Day-to-day functioning is impaired in major depressive disorder. Yet there are no guidelines to systematically assess these functional changes. This report evaluates prognostic utility of changes in activity ...
